We are live on ! Find out more
TXG icon

10x Genomics

324 hedge funds and large institutions have $12.8B invested in 10x Genomics in 2021 Q1 according to their latest regulatory filings, with 78 funds opening new positions, 128 increasing their positions, 87 reducing their positions, and 59 closing their positions.

New
Increased
Maintained
Reduced
Closed

47% more repeat investments, than reductions

Existing positions increased: 128 | Existing positions reduced: 87

36% more capital invested

Capital invested by funds: $9.38B → $12.8B (+$3.38B)

32% more first-time investments, than exits

New positions opened: 78 | Existing positions closed: 59

6% more funds holding

Funds holding: 305324 (+19)

0% more funds holding in top 10

Funds holding in top 10: 1010 (0)

0.66% less ownership

Funds ownership: 82.64%81.98% (-0.66%)

18% less call options, than puts

Call options by funds: $33.1M | Put options by funds: $40.3M

Holders
324
Holders Change
+19
Holders Change %
+6.23%
% of All Funds
5.69%
Holding in Top 10
10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.18%
New
78
Increased
128
Reduced
87
Closed
59
Calls
$33.1M
Puts
$40.3M
Net Calls
-$7.22M
Net Calls Change
-$25.9M

TXG Hedge Fund Activity: Q1 2021 in Review

324 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in 10x Genomics (TXG) for Q1 2021, worth a combined $12.8B — up 36% from $9.38B a quarter earlier.

Buyers outnumbered sellers: 78 funds opened new TXG positions and 59 closed out — a net gain of 19 holders — while 128 added to existing stakes and 87 trimmed.

The largest buyer was ARK Investment Management, adding an estimated $513M. The largest seller was Morgan Stanley, cutting an estimated $444M.

  • 324 institutional investors held 10x Genomics (TXG) as of Q1 2021, up from 305 in Q4 2020.
  • Funds reported $12.8B of 10x Genomics stock for Q1 2021, up 36% quarter-over-quarter.
  • 78 funds opened new 10x Genomics positions in Q1 2021 and 59 closed out, a net change of +19 holders.
  • The largest 10x Genomics buyer in Q1 2021 was ARK Investment Management, an estimated $513M added.
  • The largest 10x Genomics seller in Q1 2021 was Morgan Stanley, an estimated $444M sold.

Based on aggregated 13F filings for Q1 2021.